EGFR and neoplasm: Future strategies aim to exploit tumor microenvironment–responsive carriers (e.g., pH- or MMP-triggered nanoparticles) for on-site drug release, antibody-functionalized systems targeting EGFR or CD44 to achieve HNSCC specificity, and PLGA-based sustained‐release formulations to extend dosing intervals and improve patient compliance.